Prominent Respiratory Involvement Featured in High-Risk Screening for Late-Onset Pompe Disease in China

Backgroud: Pompe disease is a rare metabolic disorder with available enzymatic replacement therapy. Contrasting with the classic infantile form, the others subtypes have a heterogeneous presentation that makes an early and accurate diagnosis difficulty. A multicenter observational study was aimed to assess the prevalence of late-onset Pompe disease (LOPD) in high-risk population, using dried blood spot (DBS) as a main screening tool.Methods: 20 Chinese neuromuscular centers were involved in the early LOPD screening study. Inclusion criteria were: (1) age ≥1 years, (2) either one of a) persistent hyperCKemia; or b) muscle weakness of axial and/or limb-girdle muscles; or c) unexplained restrictive respiratory insufficiency. Enzymatic activity of acid α-glucosidase (GAA) was measured on DBS by tandem mass spectrometry (MS/MS) assay. For the final diagnosis genotype was assessed by next-generation sequencing.Result: In a 9-month period, we studied 492 cases: 26 positive samples (5.3%) were detected by DBS screening. Molecular studies finally confirmed LOPD diagnosis in 8 cases (1.6%). The GAA activities in individuals bearing pseudodeficiency alleles were well separated from those in LOPD patients by MS/MS assay. The median interval from the onset of symptoms to diagnosis was 5 years. Besides axial/proximal muscle weakness, all patients showed respiratory insufficiency with a mean forced vital capacity of predicted of 48%. The level of creatine kinase ranged from normal to no more than 5-fold of upper normal limit. LOPD with isolated hyperCKemia was not identified.Conclusions: This study confirms that DBS test is a reliable method for screening for LOPD. Respiratory insufficiency is earlier and more severe among Chinese LOPD patients. LOPD presented with paucisymptomatic hyperCKemia. Therefore, a prompt diagnosis is critical to prognosis.

[1]  A. Kaminska,et al.  Screening for late‐onset Pompe disease in Poland , 2019, Acta neurologica Scandinavica.

[2]  N. Karabul,et al.  Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey , 2019, JIMD reports.

[3]  Zhaoxia Wang,et al.  Characteristics of Pompe disease in China: a report from the Pompe registry , 2019, Orphanet Journal of Rare Diseases.

[4]  J. Vissing,et al.  Screening for late‐onset Pompe disease in western Denmark , 2018, Acta neurologica Scandinavica.

[5]  Y. Parman,et al.  A database for screening and registering late onset Pompe disease in Turkey , 2017, Neuromuscular Disorders.

[6]  T. Evangelista,et al.  Screening for Pompe disease in a Portuguese high risk population , 2017, Neuromuscular Disorders.

[7]  J. H. Lee,et al.  Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population , 2017, Neuromuscular Disorders.

[8]  S. Sakoda,et al.  Screening for late‐onset Pompe disease in undiagnosed myopathies , 2017 .

[9]  W. Rom,et al.  Progression from respiratory dysfunction to failure in late-onset Pompe disease , 2016, Neuromuscular Disorders.

[10]  B. Schlotter-Weigel,et al.  Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness , 2016, Neurology.

[11]  K. Berger,et al.  Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease , 2016, Neuromuscular Disorders.

[12]  Z. Lukacs,et al.  Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort , 2015, Neuromuscular Disorders.

[13]  S. García-Morillo,et al.  Delayed diagnosis of late-onset Pompe disease in patients with myopathies of unknown origin and/or hyperCKemia. , 2015, Molecular genetics and metabolism.

[14]  G. Comi,et al.  LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[16]  H. Lv,et al.  Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation , 2014, BMC Medical Genetics.

[17]  Chih-jou Lai,et al.  A large‐scale nationwide newborn screening program for pompe disease in Taiwan: Towards effective diagnosis and treatment , 2014, American journal of medical genetics. Part A.

[18]  P. Kishnani,et al.  Timing of diagnosis of patients with pompe disease: Data from the pompe registry , 2013, American journal of medical genetics. Part A.

[19]  G. Comi,et al.  Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia. , 2013, Molecular genetics and metabolism.

[20]  B. Schoser,et al.  Toward deconstructing the phenotype of late‐onset Pompe disease , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[21]  O. Migita,et al.  Newborn screening for Pompe disease in Japan. , 2011, Molecular genetics and metabolism.

[22]  Y. Chien,et al.  Rapid progressive course of later-onset Pompe disease in Chinese patients. , 2011, Molecular genetics and metabolism.

[23]  W. Hop,et al.  Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy , 2011, Orphanet journal of rare diseases.

[24]  F. Endo,et al.  High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. , 2009, Molecular genetics and metabolism.

[25]  B. Casetta,et al.  New strategy for the screening of lysosomal storage disorders: the use of the online trapping-and-cleanup liquid chromatography/mass spectrometry. , 2009, Analytical Chemistry.

[26]  J. Melvin.  Pompe's disease. , 2000, Archives of neurology.